Synthetic Biology

Synthetic biology is the project of making biology easier to engineer.

11 frameworks, from 1991 to today · Biology · Natural Sciences

still a working view ended · each leads to its entry below

Overview

Synthetic biology is the project of making biology easier to engineer1. Where molecular biologists typically take living systems apart to understand them, synthetic biologists try to build with them: to design and assemble genes, circuits, metabolic pathways, and even whole genomes that do something useful or something new1. The field's central wager is that biology can be made more like engineering—modular, predictable, and buildable from standard parts—and its history is largely the story of how far that wager has paid off, where it has failed, and how the field has repeatedly renegotiated the boundary between designing life and merely tinkering with it.

From genetic engineering to a deliberate discipline

The immediate ancestor of synthetic biology is recombinant DNA technology, developed in the early 1970s. When Stanley Cohen and Herbert Boyer showed in 1973 that DNA could be cut, joined, and cloned into bacteria, they gave biology its first general method for moving genes between organisms. That work also triggered the field's first governance crisis: the 1975 Asilomar conference on recombinant DNA, where scientists agreed on voluntary containment guidelines, established a template for self-regulation that synthetic biology would later inherit and argue over.

Through the 1980s and 1990s, genetic engineering matured into a workhorse of biotechnology—insulin-producing bacteria, engineered crops, transgenic mice. But it remained largely bespoke. Each new construct was a one-off, assembled by trial and error, and the field had little in the way of reusable standards. The term "synthetic biology" appeared sporadically in this period, but the discipline that would claim the name took shape around 2000.

The founding gestures: circuits and standardized parts

Two papers in January 2000 are conventionally treated as the field's founding moments. Michael Elowitz and Stanislas Leibler built a "repressilator" in E. coli: three repressor genes wired so that each shut off the next, producing a ring of negative feedback that made the bacteria blink fluorescently. In the same issue of Nature, Tim Gardner, Charles Cantor, and James Collins built a genetic toggle switch—two mutually repressing genes that could be flipped between two stable states by chemical signals. Neither circuit was useful in an industrial sense. Their importance was conceptual: they showed that small networks of genes could be designed to perform a logical function, the way an electronic circuit does.

Around the same time, Drew Endy and colleagues began arguing that biology needed a parts regime2. The idea, crystallized in the MIT Registry of Standard Biological Parts (founded in 2003), was that DNA sequences encoding promoters, ribosome binding sites, and coding regions could be standardized—flanked by defined restriction sites so they could be snapped together like Lego—and catalogued with documented behavior. This "parts-based" approach, sometimes called the "BioBrick" standard after the assembly method, became the intellectual core of the field's early self-image1. It also seeded the International Genetically Engineered Machine (iGEM) competition, begun in 2004, in which student teams build organisms from registry parts; iGEM became the field's most effective training ground and a durable source of new practitioners.

The design–build–test cycle and its discontents

The parts program came with a methodology: the design–build–test cycle. You design a construct, build the DNA, test it in a cell, learn from the failure, and redesign. This loop, borrowed from engineering, framed synthetic biology as an iterative discipline in which each cycle would produce more reliable components.

In practice, the cycle exposed a problem the electronics metaphor had obscured. Biological parts do not behave like electronic ones. A promoter's strength depends on the cell it sits in, on the surrounding DNA, on the growth conditions, and on the load it places on the host's resources. In 2009, a group led by Drew Endy (with Barry Canton and Anna Labno) published a widely discussed critique arguing that the field's parts were poorly characterized and that retrofitting existing natural systems was harder than the rhetoric suggested. The response was a shift toward better measurement, standardized characterization, and a more honest accounting of context-dependence—and, more broadly, a recognition that biology's messiness could not be engineered away by fiat.

Chassis engineering and the host as a designed object

If parts were unreliable, one reason was the cell around them. "Chassis" became the field's word for the host organism—usually E. coli or yeast—treated as a platform to be optimized. Early chassis work focused on removing unnecessary functions: in 2002, a team including Hirotada Mori and colleagues reported large-scale deletions in E. coli to create a reduced-genome strain, and later efforts pushed further toward "minimal" cells. The most celebrated result came in 2016, when Clyde Hutchison, John Glass, and colleagues at the J. Craig Venter Institute reported a synthetic minimal bacterial genome, Mycoplasma mycoides JCVI-syn3.0, built from a chemically synthesized sequence and stripped to roughly 473 genes—enough to sustain life, though the functions of many of those genes remained unknown. Chassis engineering also drove work on orthogonal systems: hosts engineered so that synthetic components do not interfere with native ones, and vice versa.

Metabolic engineering: the industrial wing

Running alongside the circuits-and-parts story was a more commercially oriented tradition. Metabolic engineering—the directed modification of an organism's metabolism to overproduce a chemical—predates the synthetic biology label, with roots in the 1980s and 1990s work of people like James Bailey and Gregory Stephanopoulos. Its logic is different from circuit design: rather than building logic gates, you reroute fluxes through pathways, delete competing reactions, and balance cofactors so that a cell makes a target molecule efficiently.

The two traditions converged in the 2000s. The antimalarial drug precursor artemisinic acid became the flagship case: Jay Keasling's group at UC Berkeley, with Amyris and later Sanofi, engineered yeast to produce it through a long pathway assembled from plant, bacterial, and yeast genes, and by the mid-2010s the process was supplying a meaningful share of the world's artemisinin supply. Similar programs followed for biofuels, flavors, and specialty chemicals. Metabolic engineering gave synthetic biology its clearest industrial justification and its most direct line to commercial scale.

Systems and computational design

As constructs grew more complex, the field turned to computation. Systems biology supplied the modeling vocabulary—ordinary differential equations for gene networks, parameter estimation from data, sensitivity analysis—and synthetic biologists adopted it to predict circuit behavior before building. Software tools such as BioBrick assembly planners, the Synthetic Biology Open Language (SBOL) for representing designs, and later machine-learning approaches for predicting promoter strength and protein expression became part of the standard toolkit. The aspiration was a design environment in which a specification could be compiled into DNA; the reality has been more modest, with computation serving mainly to narrow the search space and flag likely failures.

Cell-free systems: taking the cell out of the loop

A parallel strand asked whether the cell was necessary at all. Cell-free synthetic biology uses extracts of cells—or defined mixtures of purified components—to carry out transcription and translation outside a living organism. The approach has older roots in the 1960s, when researchers used cell extracts to decipher the genetic code, but its synthetic-biology incarnation dates from the 2000s and 2010s, when groups including those of James Swartz and Michael Jewett showed that cell-free systems could produce proteins at useful yields and could be used for rapid prototyping of genetic circuits. Cell-free systems sidestep many of the context problems of living chassis: you can add components directly, measure without worrying about growth, and avoid the containment issues of engineered organisms. They have become a practical platform for diagnostics, for producing toxic proteins, and for teaching.

Synthetic genomics and genome editing

The most ambitious strand is synthetic genomics: building genomes from scratch. The Venter Institute's work progressed from synthesizing a viral genome in 2003, to the first synthetic bacterial genome (a Mycoplasma genitalium sequence, 2008), to the 2010 "synthetic cell" in which a chemically synthesized M. mycoides genome was transplanted into a recipient cell and took over its operation, and then to the minimal genome of 2016. In parallel, the Sc2.0 project, an international consortium, set out to synthesize a fully synthetic version of the yeast genome, with designer features such as scrambled gene order and removable sections; by the late 2010s and early 2020s, multiple synthetic yeast chromosomes had been built and shown to function.

Genome editing, especially CRISPR–Cas9, developed from 2012 onward by Jennifer Doudna, Emmanuelle Charpentier, and others, changed the field's relationship to its own materials134. Editing made it possible to modify existing genomes precisely and cheaply, which both competed with and complemented the build-from-scratch ethos. Many synthetic biologists now treat editing as one more construction tool in the design–build–test cycle rather than as a separate enterprise.

Biosafety, biosecurity, and governance

From Asilomar onward, synthetic biology has been accompanied by an argument about risk. The field's early self-governance—the 2006 Sloan Foundation–funded report on synthetic genomics, the 2010 Presidential Commission report, and the 2012 "Synthetic Biology" statement from the European Group on Ethics—focused on accidental release, dual-use research, and the adequacy of existing regulations. The 2011 controversy over H5N1 avian influenza gain-of-function experiments, and later debates over the synthesis of horsepox virus in 2017, sharpened concerns about the ease of ordering DNA and the difficulty of screening. Governance responses have been patchy: voluntary DNA synthesis screening by industry, national biosafety regimes that vary widely, and ongoing debate about whether synthetic biology needs rules distinct from those governing recombinant DNA. The field's practitioners have generally favored self-regulation, while critics have argued that the pace of technical capability outruns the institutions meant to oversee it.

Where the field stands

Synthetic biology today is less a single program than a family of approaches sharing a commitment to deliberate construction1. The parts-based ideal survives in standardized assembly methods and registries, but practitioners have largely abandoned the hope that biology would become as predictable as electronics; context-dependence, evolution, and the sheer complexity of cells remain stubborn. Metabolic engineering and cell-free systems are the most industrially mature strands. Genome editing and synthetic genomics push at the boundaries of what counts as "synthetic." The open questions are the ones the field has carried since 2000: how to make designed biological systems reliable, how to govern them without stifling them, and whether the engineering metaphor is the right frame for organisms at all—or whether biology will always resist being built the way machines are.

References

  1. Synthetic biology (introduction, Modularity, History), Wikipedia
  2. BioBrick (History), Wikipedia
  3. CRISPR gene editing, Wikipedia
  4. CRISPR, Wikipedia

The frameworks of Synthetic Biology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1991-Present
  2. 2000-Present
  3. 2000-Present
  4. 2002-Present
  5. 2003-Present
  6. 2003-Present
  7. 2003-Present
  8. 2004-Present
  9. 2004-Present
  10. 2006-Present
  11. 2012-Present
A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Synthetic Biology is a planet in Nousfarer

Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.

Land on Synthetic Biology

Related fields

More in Biology

See where Synthetic Biology sits on the Map of Human Knowledge